The initial public offering (IPO) market has grown cold as global markets have been sliding in 2016, and many companies are choosing to postpone their IPOs for more favorable market conditions. Therapure Biopharma is no exception. The company announced that, due to current conditions in capital markets, it would postpone its offering.
While the company is performing above expectations and investor feedback about the quality of management and the company was very positive, Therapure makes this decision in light of the current market environment, in which no IPOs were concluded in the United States or Canada in January.
The underwriters for the offering are GMP Securities, CIBC World Markets and National Bank Financial.
For some background on the company:
Therapure is a biopharmaceutical company focused on manufacturing complex biologics for its customers and on developing, manufacturing and selling its own blood and plasma-related therapeutic products. Its passion for quality and patient safety underpins everything it does in its three divisions: Therapure Biomanufacturing, an award-winning contract development and manufacturing division; Therapure Biologics, a division focused on using its proprietary PlasmaCap EBA technology to develop a portfolio of plasma-derived pharmaceutical products; and Therapure Innovations, a proprietary therapeutics and platform technologies research and development division.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
